enGene Therapeutics (ENGN) Accumulated Expenses (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Accumulated Expenses of $2.2 million for Q2 2026, down 82.71% year-over-year from $12.4 million in Q2 2025, and down 89.07% quarter-over-quarter from $19.7 million in Q1 2026.
enGene Therapeutics (ENGN) Accumulated Expenses (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Accumulated Expenses for 5 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses fell 82.71% year-over-year to $2.2 million; the TTM figure through Apr 2026 stood at $2.2 million (down 82.71% YoY), while the FY2025 annual figure was $15.3 million, up 339.57% from the prior year.
- Accumulated Expenses fell to $2.2 million in Q2 2026 per ENGN's latest filing, from $19.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $19.7 million in Q1 2026 and bottomed at $676000.0 in Q4 2022.
- Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $4.6 million in 2024.
- Annual changes were most pronounced in 2025 — Accumulated Expenses surged 430.16% — and 2026, when it plunged 82.71%.
- enGene Therapeutics' Accumulated Expenses stood at $676000.0 in 2022, then grew by 20.41% to $814000.0 in 2023, then jumped by 326.9% to $3.5 million in 2024, then jumped by 339.57% to $15.3 million in 2025, then slumped by 85.92% to $2.2 million in 2026.
- Business Quant data shows ENGN's Accumulated Expenses at $2.2 million in Q2 2026, $19.7 million in Q1 2026, and $15.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.15 Mn |
| Jan 31, 2026 | 19.67 Mn |
| Oct 31, 2025 | 15.28 Mn |
| Jul 31, 2025 | 2.91 Mn |
| Apr 30, 2025 | 12.43 Mn |
| Jan 31, 2025 | 8.24 Mn |
| Oct 31, 2024 | 3.48 Mn |
| Jul 31, 2024 | 8.83 Mn |
| Apr 30, 2024 | 5.67 Mn |
| Jan 31, 2024 | 1.56 Mn |
| Oct 31, 2023 | 814,000.00 |
| Oct 31, 2022 | 676,000.00 |